Evozyne utilizes generative AI to design novel protein systems for therapeutic discovery and drug development, addressing the need for more effective and targeted treatments. By enhancing the efficiency of drug development processes, Evozyne aims to accelerate the delivery of innovative therapies to improve patient outcomes.
Funding
$135.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FFounders
Product
Problem
Traditional therapeutic discovery and drug development processes often face challenges in identifying and optimizing protein systems for effective and targeted treatments. This can lead to inefficiencies in drug development and delay the delivery of innovative therapies.
Solution
Evozyne leverages generative AI to design novel protein systems, addressing the limitations of conventional therapeutic discovery and drug development. By applying advanced machine learning algorithms, Evozyne can explore a vast design space and identify protein variants with enhanced functionality and therapeutic potential. This approach accelerates the drug development pipeline, enabling the creation of more effective and targeted treatments. Evozyne's technology facilitates the optimization of protein-based therapeutics, improving their efficacy and reducing potential side effects. The company's platform aims to deliver innovative therapies more rapidly, ultimately improving patient outcomes.
Target Audience
Evozyne's primary customers are pharmaceutical companies and research institutions involved in therapeutic discovery and drug development.
Features
- Generative AI platform for de novo protein design and optimization
- Machine learning algorithms to predict protein structure and function
- High-throughput virtual screening to identify promising therapeutic candidates
- Computational protein engineering to enhance protein stability and activity